Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Harmony Biosciences Holdings heads into its October 27 earnings report with short sellers rebuilding positions and options traders leaning heavily defensive, even as the analyst community remains broadly constructive on the WAKIX franchise.
The most striking development this week is the pace of short positioning. Short interest climbed 17% over the past week to 9.65% of the free float, and is up 35% over the past month. That puts it back near levels last seen in September before a brief unwind. The move is directionally notable because borrow conditions have not tightened to match: availability runs at 688%, meaning roughly seven shares remain available to borrow for every one already lent out, well above the 52-week tightest reading of 591%. Cost to borrow has actually fallen, dropping 42% on the week to just 0.34%, the lowest in thirty days. Short sellers are adding with ease. The borrow market is not signalling any squeeze pressure, which makes the position build a deliberate bet rather than a trapped short.
Options tell a compatible story. The put/call ratio has jumped to 2.35, running about 1.5 standard deviations above its 20-day average of 1.92. That is close to the most defensive reading of the past three weeks, though it sits below the 52-week peak of 2.89 touched in September. Earnings land nine days away, and the options skew suggests hedging demand is outpacing outright bullish positioning. The ORTEX short score is at 57, up from 54 at the start of the month, a modest but consistent move in the bearish direction.
The Street, by contrast, remains broadly positive. The consensus is a buy, with a mean price target of $48.25 against the current price of $37.95, implying roughly 27% upside. This week, HC Wainwright and Needham each reiterated buy ratings with targets of $55 and $50 respectively. The bull case centres on WAKIX momentum, with 2026 net revenue guidance reaffirmed at $1.00 billion to $1.04 billion, net patient additions running at plus 450 in the last quarter, and a pipeline spanning BP-205, EPX-100, and ZYN002 that gives the company multiple growth vectors. The bear case is more concentrated: WAKIX contributes nearly all revenue, and any competition in the sodium oxybate space or setbacks in rare-disease trials would hit the business hard. Truist and Deutsche Bank both hold sidelined ratings with targets well below the buy-side cluster, at $34 and $36 respectively. Valuation multiples look undemanding for a profitable speciality pharma, with a price-to-earnings ratio below 6 and EV/EBITDA at 4.8, both compressing further over the past month as the stock has pulled back 10%.
One real-economy data point worth noting: CMS Medicaid reimbursement data for Harmony's drugs showed $38.7 million reimbursed in Q1 2026, up 20% on the same quarter a year earlier. That marks four consecutive quarters of rising Medicaid reimbursements. The Medicaid drugs dataset from the Centers for Medicare and Medicaid Services has not been measured as a leading indicator of reported financials, so it is colour rather than a preview of the print, but the trajectory is consistent with the patient-growth narrative the bulls are running with.
On the ownership side, BlackRock holds 12.2% as the largest institutional holder, adding 539,000 shares through September. American Century added 486,000 shares over the same period and Fidelity put on 416,000. Dimensional and State Street also added. The CMO, Budur Kumar, exercised options and sold shares in mid-September, netting a disposal of roughly $3.1 million on a 90-day basis, though the trades were paired option exercises and open-market sales rather than discretionary selling at current prices, a mechanical pattern rather than an outright conviction signal.
Correlated peers had a rough week. GPCR fell 17% and ZVRA dropped 13%, suggesting broader pressure on small-cap CNS and rare-disease names. HRMY held up better with a 6% decline, but the peer weakness is the backdrop against which shorts are rebuilding. The October 27 print is next: the prior quarter produced a 7% one-day move higher, and the quarter before that was essentially flat. With bears building and options skew elevated, the market is paying for protection rather than expressing conviction in either direction.
See the live data behind this article on ORTEX.
Open HRMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
